Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer

Brain metastases (BMs) are common in small cell lung cancer (SCLC), and the efficacy of immune checkpoint inhibitors (ICIs) in these patients is uncertain. In this study we aimed to develop and validate a radiomics nomogram based on magnetic resonance imaging (MRI) for intracranial efficacy prediction of ICIs in patients with BMs from SCLC.

[1]  M. Zeng,et al.  Evaluating Histological Subtypes Classification of Primary Lung Cancers on Unenhanced Computed Tomography Based on Random Forest Model , 2023, Journal of healthcare engineering.

[2]  Yan Wang,et al.  Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice , 2022, Thoracic cancer.

[3]  Y. Guo,et al.  MRI-based radiomics analysis in differentiating solid non-small-cell from small-cell lung carcinoma: a pilot study. , 2022, Clinical radiology.

[4]  A. Sahgal,et al.  Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. , 2022, The Lancet. Oncology.

[5]  Edward S. Kim,et al.  Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial , 2022, Nature Medicine.

[6]  Yixian Guo,et al.  Progression-Free Survival Prediction in Small Cell Lung Cancer Based on Radiomics Analysis of Contrast-Enhanced CT , 2022, Frontiers in Medicine.

[7]  M. Smits,et al.  Brain metastases: the role of clinical imaging , 2021, The British journal of radiology.

[8]  A. Sahgal,et al.  A priori prediction of local failure in brain metastasis after hypo-fractionated stereotactic radiotherapy using quantitative MRI and machine learning , 2021, Scientific Reports.

[9]  A. Madabhushi,et al.  Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[10]  Sachin B. Malik,et al.  Machine Learning Radiomics Model for Early Identification of Small-Cell Lung Cancer on Computed Tomography Scans. , 2021, JCO clinical cancer informatics.

[11]  Hu Liu,et al.  Radiomics-Based Features for Prediction of Histological Subtypes in Central Lung Cancer , 2021, Frontiers in Oncology.

[12]  J. Ji,et al.  Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE , 2021, European Radiology.

[13]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[14]  S. Gettinger,et al.  Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  N. Reinmuth,et al.  Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Reinmuth,et al.  Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[17]  Shunli Liu,et al.  Exploratory Study of a CT Radiomics Model for the Classification of Small Cell Lung Cancer and Non-small-Cell Lung Cancer , 2020, Frontiers in Oncology.

[18]  G. Botti,et al.  Immunotherapy in Small Cell Lung Cancer , 2020, Cancers.

[19]  S. Batra,et al.  Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach , 2020, Frontiers in Oncology.

[20]  L. Horn,et al.  Immunotherapeutic approaches for small-cell lung cancer , 2020, Nature Reviews Clinical Oncology.

[21]  Jing Zhang,et al.  A clinical-radiomics nomogram for the preoperative prediction of lymph node metastasis in colorectal cancer , 2020, Journal of Translational Medicine.

[22]  Anne L. Martel,et al.  Use of Radiomics for the Prediction of Local Control of Brain Metastases After Stereotactic Radiosurgery. , 2020, Neuro-oncology.

[23]  Gregory J. Czarnota,et al.  Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis , 2019, Scientific Reports.

[24]  Young Hak Kim,et al.  Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial , 2019, The Lancet.

[25]  Yi-bin Xi,et al.  MRI-based radiomics nomogram may predict the response to induction chemotherapy and survival in locally advanced nasopharyngeal carcinoma , 2019, European Radiology.

[26]  O. Molinier,et al.  A Randomized Non‐Comparative Phase II Study of Anti‐Programmed Cell Death‐Ligand 1 Atezolizumab or Chemotherapy as Second‐Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT‐1603 Trial , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[28]  J. Welsh,et al.  Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  Yanqi Huang,et al.  Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Ricken,et al.  Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC) , 2016, Journal of Neuro-Oncology.

[31]  Camel Tanougast,et al.  Extracted magnetic resonance texture features discriminate between phenotypes and are associated with overall survival in glioblastoma multiforme patients , 2016, Medical & Biological Engineering & Computing.

[32]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[33]  Susan M. Chang,et al.  Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.

[34]  Li Zhang,et al.  Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Ling,et al.  The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer , 2014, British Journal of Cancer.

[36]  J. Tichelaar,et al.  Mouse models of chemically-induced lung carcinogenesis. , 2013, Frontiers in bioscience.

[37]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[38]  Pieter Leffers,et al.  Detection of brain metastases from small cell lung cancer , 2008, Cancer.